Leana Wen Acquires Shares in URGN
Leana Wen bought 8,000 shares of URGN on June 22, 2026.
Key Points
- Leana Wen purchased 8,000 shares of URGN on June 22, 2026, with the stock trading near $35.8.
- URGN has a range of institutional investors including BlackRock, which increased its holdings by 244,558 shares.
- Analysts like HC Wainwright & Co. and Oppenheimer maintained 'buy' ratings with price targets of $45 and $40 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Leana Wen made a notable move by purchasing 8,000 shares of URGN on June 22, 2026. The transaction was not part of a pre-planned trading arrangement, suggesting a direct interest in the company's prospects. On the transaction date, URGN's shares were trading near $35.8.
Other Institutional Activity in URGN
Several institutional investors have shown interest in URGN. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at approximately $51.2 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares worth about $47 million. Kynam Capital Management, LP also initiated a stake, acquiring 2,247,393 shares valued at roughly $40.4 million. Meanwhile, Morgan Stanley slightly trimmed its position by 2,863 shares, holding 2,560,038 shares valued around $46 million.
UroGen Pharma Ltd. Stock Down 18.4%
Shares of URGN traded near $35.8 on Wednesday. The company's stock has attracted attention from various institutional investors, indicating a keen interest in its market potential. While the fundamentals of URGN are not detailed here, the stock's price movement and institutional activity suggest a dynamic trading environment.
$URGN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at UroGen Pharma Ltd.
In addition to Leana Wen's purchase, several other insiders bought shares on June 22, 2026. Robinson James Jr. acquired a total of 18,000 shares, while Arie Belldegrun purchased 20,000 shares. Cynthia Butitta and Daniel George Wildman each bought 10,000 shares. These transactions were not executed under Rule 10b5-1 plans, indicating direct insider interest.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on URGN. On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $45. Oppenheimer also kept a 'buy' rating, setting a target at $40 on May 7, 2026. The consensus remains favorable, with several firms endorsing the stock's potential.
Bottom Line
Leana Wen's recent purchase of URGN shares adds to the interest from institutional and insider investors. While these transactions reflect confidence in the company's future, it's essential to remember that such filings are backward-looking and may not represent current positions. Investors often track insider and institutional activities for insights into the company's market perception.
Get UroGen Pharma Ltd. alerts
New 13F filings, insider trades, and analyst moves on $URGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.